NU641 Final and Midterm Exam Prep
Test Bank Latest With 400+ Questions
and Correct Verified Answers/ NU641
Advanced Clinical Pharmacology Prep
Test Bank for Midterm and Final Exam
Section A: Pharmacokinetics & Pharmacodynamics (Questions 1-
40)
1. The nurse practitioner is teaching a patient about a newly prescribed medication
that has a narrow therapeutic index. Which statement by the patient indicates
understanding?
A) "I can take this medication whenever I remember to take it."
B) "I need to have my blood levels checked regularly to make sure the dose is
safe."
C) "If I miss a dose, I should double the next dose."
D) "I can stop this medication when I feel better."
Answer: B
Rationale: Drugs with a narrow therapeutic index require therapeutic drug monitoring
to maintain levels within the therapeutic range and avoid toxicity. Patient education
should emphasize the importance of regular monitoring and adherence.
2. A drug that is a weak acid with a pKa of 4.4 will be MOST absorbed in which
part of the gastrointestinal tract?
,A) Small intestine (pH 6.5)
B) Stomach (pH 2.0)
C) Colon (pH 7.0)
D) Blood (pH 7.4)
Answer: B
Rationale: Weak acids are best absorbed in acidic environments where they remain
non-ionized. The stomach (pH 2.0) favors absorption of weak acids. In alkaline
environments, they become ionized and poorly absorbed.
3. The primary site of drug metabolism in the body is the:
A) Kidney
B) Liver
C) Lung
D) Intestine
Answer: B
Rationale: The liver contains cytochrome P450 (CYP450) enzymes, the primary site of
drug metabolism. The liver is responsible for biotransformation of most medications
through Phase I and Phase II reactions.
4. Which of the following best describes the first-pass effect?
A) Metabolism of a drug in the kidneys before excretion
B) Metabolism of an orally administered drug in the liver before reaching systemic
circulation
C) Binding of drugs to plasma proteins
D) Distribution of drugs to target tissues
Answer: B
Rationale: The first-pass effect refers to hepatic metabolism of orally administered
drugs before they enter systemic circulation. Drugs absorbed from the GI tract travel via
,the portal vein to the liver, where they may be significantly metabolized, reducing
bioavailability.
5. The time required for a drug concentration to decrease by 50% in the body is
called:
A) Therapeutic index
B) Half-life
C) Volume of distribution
D) Clearance
Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration of a drug to
decrease by 50%. It is a key pharmacokinetic parameter that determines dosing
intervals.
6. A patient with hepatic cirrhosis is prescribed a medication that is extensively
metabolized by the liver. The NP should anticipate:
A) Increased drug clearance
B) Decreased drug metabolism and increased drug levels
C) No change in drug metabolism
D) Increased renal excretion
Answer: B
Rationale: Hepatic cirrhosis reduces liver function, decreasing metabolism of hepatically
cleared drugs. This leads to increased drug levels and risk of toxicity. Dose adjustments
are often necessary.
7. A patient with renal impairment is prescribed a renally cleared medication.
What is the appropriate action?
, A) Increase the dose
B) Decrease the dose or extend the dosing interval
C) Administer the medication IV
D) No change is needed
Answer: B
Rationale: Reduced renal function decreases drug clearance, requiring dose reduction
or extended dosing intervals to prevent drug accumulation and toxicity. Dosage should
be based on eGFR.
8. Which of the following is a CYP450 enzyme inhibitor?
A) Rifampin
B) Ketoconazole
C) Phenytoin
D) Carbamazepine
Answer: B
Rationale: Ketoconazole is a potent CYP3A4 inhibitor that increases levels of co-
administered drugs metabolized by CYP3A4, raising toxicity risk. Rifampin, phenytoin,
and carbamazepine are inducers.
9. A patient on warfarin is started on rifampin. What is the expected effect on the
INR?
A) Increased INR, increased bleeding risk
B) Decreased INR, reduced anticoagulation
C) No change in INR
D) Immediate warfarin toxicity
Answer: B
Test Bank Latest With 400+ Questions
and Correct Verified Answers/ NU641
Advanced Clinical Pharmacology Prep
Test Bank for Midterm and Final Exam
Section A: Pharmacokinetics & Pharmacodynamics (Questions 1-
40)
1. The nurse practitioner is teaching a patient about a newly prescribed medication
that has a narrow therapeutic index. Which statement by the patient indicates
understanding?
A) "I can take this medication whenever I remember to take it."
B) "I need to have my blood levels checked regularly to make sure the dose is
safe."
C) "If I miss a dose, I should double the next dose."
D) "I can stop this medication when I feel better."
Answer: B
Rationale: Drugs with a narrow therapeutic index require therapeutic drug monitoring
to maintain levels within the therapeutic range and avoid toxicity. Patient education
should emphasize the importance of regular monitoring and adherence.
2. A drug that is a weak acid with a pKa of 4.4 will be MOST absorbed in which
part of the gastrointestinal tract?
,A) Small intestine (pH 6.5)
B) Stomach (pH 2.0)
C) Colon (pH 7.0)
D) Blood (pH 7.4)
Answer: B
Rationale: Weak acids are best absorbed in acidic environments where they remain
non-ionized. The stomach (pH 2.0) favors absorption of weak acids. In alkaline
environments, they become ionized and poorly absorbed.
3. The primary site of drug metabolism in the body is the:
A) Kidney
B) Liver
C) Lung
D) Intestine
Answer: B
Rationale: The liver contains cytochrome P450 (CYP450) enzymes, the primary site of
drug metabolism. The liver is responsible for biotransformation of most medications
through Phase I and Phase II reactions.
4. Which of the following best describes the first-pass effect?
A) Metabolism of a drug in the kidneys before excretion
B) Metabolism of an orally administered drug in the liver before reaching systemic
circulation
C) Binding of drugs to plasma proteins
D) Distribution of drugs to target tissues
Answer: B
Rationale: The first-pass effect refers to hepatic metabolism of orally administered
drugs before they enter systemic circulation. Drugs absorbed from the GI tract travel via
,the portal vein to the liver, where they may be significantly metabolized, reducing
bioavailability.
5. The time required for a drug concentration to decrease by 50% in the body is
called:
A) Therapeutic index
B) Half-life
C) Volume of distribution
D) Clearance
Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration of a drug to
decrease by 50%. It is a key pharmacokinetic parameter that determines dosing
intervals.
6. A patient with hepatic cirrhosis is prescribed a medication that is extensively
metabolized by the liver. The NP should anticipate:
A) Increased drug clearance
B) Decreased drug metabolism and increased drug levels
C) No change in drug metabolism
D) Increased renal excretion
Answer: B
Rationale: Hepatic cirrhosis reduces liver function, decreasing metabolism of hepatically
cleared drugs. This leads to increased drug levels and risk of toxicity. Dose adjustments
are often necessary.
7. A patient with renal impairment is prescribed a renally cleared medication.
What is the appropriate action?
, A) Increase the dose
B) Decrease the dose or extend the dosing interval
C) Administer the medication IV
D) No change is needed
Answer: B
Rationale: Reduced renal function decreases drug clearance, requiring dose reduction
or extended dosing intervals to prevent drug accumulation and toxicity. Dosage should
be based on eGFR.
8. Which of the following is a CYP450 enzyme inhibitor?
A) Rifampin
B) Ketoconazole
C) Phenytoin
D) Carbamazepine
Answer: B
Rationale: Ketoconazole is a potent CYP3A4 inhibitor that increases levels of co-
administered drugs metabolized by CYP3A4, raising toxicity risk. Rifampin, phenytoin,
and carbamazepine are inducers.
9. A patient on warfarin is started on rifampin. What is the expected effect on the
INR?
A) Increased INR, increased bleeding risk
B) Decreased INR, reduced anticoagulation
C) No change in INR
D) Immediate warfarin toxicity
Answer: B
